BioInfra Co., Ltd. (KOSDAQ:199730)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,165.00
-20.00 (-0.48%)
At close: Apr 28, 2026
-33.47%
Market Cap 20.26B
Revenue (ttm) 23.15B
Net Income (ttm) -9.13B
Shares Out 4.86M
EPS (ttm) -1,877.00
PE Ratio n/a
Forward PE n/a
Dividend 300.00 (7.20%)
Ex-Dividend Date Dec 29, 2025
Volume 7,233
Average Volume 8,137
Open 4,205.00
Previous Close 4,185.00
Day's Range 4,145.00 - 4,260.00
52-Week Range 3,200.00 - 6,700.00
Beta 0.32
RSI 56.09
Earnings Date n/a

About BioInfra

BioInfra Co., Ltd. operates as a contract research organization for phase 1 clinical trials. The company provides clinical, which undertakes clinical trials for new drug development approval (Phase I-III) and late clinical trials; immunoassay, which performs pharmacokinetic, toxicokinetic, and biomarker analysis of polymer biopharmaceuticals; and testing and inspection, which provides finished drug product quality inspection, comparative dissolution testing, and long-term stability testing. It also specializes in bioequivalence testing of gener... [Read more]

Industry Commercial Physical and Biological Research
Founded 2007
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 199730
Full Company Profile

Financial Performance

In 2025, BioInfra's revenue was 23.15 billion, a decrease of -2.87% compared to the previous year's 23.83 billion. Losses were -9.13 billion, 129.7% more than in 2024.

Financial Statements

News

There is no news available yet.